This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.
Hyperprolactinaemia is a condition characterized by an elevated level of prolactin in the blood.1 The consequences of this imbalance are varied but most commonly lead to hypogonadism, resulting in infertility, low libido, decreased bone mass, and, in women, oligomenorrhoea and/or amenorrhoea.1
Hyperprolactinaemia occurs more frequently in women than men.1
The prevalence of hyperprolactinaemia varies based on the population under investigation.
It is:1-3
• 0.4% in the general population
• 9%-17% in women with reproductive diseases
• 16%-30% in women with infertility
• ~ 5% among men who present with impotence or infertility
Prolactin, which is synthesized by the pituitary gland, primarily functions to stimulate and maintain the production of breast milk during pregnancy and breastfeeding.1,4
When prolactin levels are elevated in either women or men, gonadotropin-releasing hormone (GnRH) secretion is inhibited and gonadal function is affected, ultimately leading to infertility.4,5
Adapted from Kaiser UK, 2012.6
Hyperprolactinaemia can arise from pharmacologic, pathologic, physiologic, and idiopathic causes.1
Prolactinomas are the most common cause of hyperprolactinaemia, which account for approximately 40% of all pituitary tumors.7
It is important to be aware that several different types of medications and drugs can cause increased serum prolactin levels.
Adapted from Vilar L., et al and Peña KS., et al.
Please note some of these medications are not available in the UK
Estring (estradiol hemihydrate) prescribing information can be found here
Premarin (oestrogens, conjugated) prescribing information can be found here
Premique (medroxyprogesterone acetate oestrogens, conjugated) prescribing information can be found here
References
Understand what signs to look for and explore two patient case studies
Recognise which tests to order and what the results indicate
Determine therapy based on clinical and patient factors
Learn how to tailor therapy based on follow-up testing
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021